Read our Recent Headlines

February 15th Biotech Update

Not surprisingly we are in a post earnings lull. While there are still earnings being posted, the bulk of the major ones have been reported. We are also seeing the.

February 13th Biotech Update

The sector continues to do well this week on not necessarily all positive news. My refrain will continue to be that we are range bound until proven otherwise and so.

February 12 Biotech Update

We have some interesting news today (positive and negative) with some interesting read through. I still think the base case is that the sector is in a range until proven.

February 7 Biotech Update

We start off a little weak this morning, which is not completely unexpected given that we are at the top end of the recent range. Obviously it would be nice.

February 6 Biotech Update

The sector faded yesterday and seems to be in a little range between $80 and $86. This is not necessarily a bad thing after the big bounce we had. Sitting.

February 5 Biotech Update

There might be reason for optimism in the sector. The XBI seems to be breaking above its recent range and the $80 level might have been support for this new.

February 1st Biotech Update

The sector seems to have gotten its footing in a way I was not expecting. Perhaps there is a bigger underlying bid than I thought. Perhaps the dovish turn in.



Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!